<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146140">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01707186</url>
  </required_header>
  <id_info>
    <org_study_id>2010930</org_study_id>
    <nct_id>NCT01707186</nct_id>
  </id_info>
  <brief_title>Pictorial Representation of Illness and Self Measure</brief_title>
  <acronym>PRISM</acronym>
  <official_title>Pictorial Representation of Illness and Self Measure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>United Kingdom: National Health Service</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRISM (Pictorial Representation of Illness and Self Measure) has been developed since the
      mid-1990s; the task was first developed as a simple measure of how a person was coping with
      his or her experience of illness.  This is an international, multicentre study to evaluate
      the PRISM tool for the assessment of suffering in rheumatoid arthritis at different stages
      of the illness and the effect of treatment intervention.  There are 5 sites: Berlin, Oxford,
      Limoges, Montreal and Queensland.  The study will recruit 200 patients in total.

      In addition to the procedures for the patient's routine clinical visit, the patients will be
      invited to answer a series of questionnaires and donate 20ml blood sample. Patients will be
      asked to attend 3 times over 24 weeks
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <number_of_groups>4</number_of_groups>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Group 1A</arm_group_label>
    <description>Early phase, requiring change in treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Established phase, stable treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A</arm_group_label>
    <description>Established phase, requiring a change in treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Early phase, stable treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with rheumatoid arthritis from hospital clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is willing and able to give informed consent for participation in the
             study.

          -  Male or Female, aged 18 years or above.

          -  Written confirmed diagnosed of rheumatoid arthritis

        Exclusion Criteria:

          -  A diagnosis of any of the following:

          -  Multiple sclerosis

          -  Motor neurone disease

          -  Parkinson's disease

          -  Alzheimer's disease

          -  Depression or anxiety disorders as identified using the Patient depression screening
             questions from the patient health questionnaire 9 (PHQ9).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Peter Taylor, FRCP, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine McClinton</last_name>
    <phone>+441865 737838</phone>
    <email>catherine.mcclinton@kennedy.ox.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nuffield Orthopaedic Centre</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine McClinton</last_name>
      <phone>+441865 737838</phone>
      <email>catherine.mcclinton@kennedy.ox.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Peter Taylor</last_name>
      <phone>+441865 227323</phone>
      <email>peter.taylor@kennedy.ox.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Peter C Taylor, FRCP. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 19, 2012</lastchanged_date>
  <firstreceived_date>October 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
